PE20160195A1 - Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington - Google Patents

Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Info

Publication number: PE20160195A1
Authority: PE; Peru
Prior art keywords: pridopidine; patient; treatment; high doses; huntington
Prior art date: 2013-06-21

Application number

PE2015002618A

Other languages

English (en)

Spanish (es)

Inventor

Esther Lukasiewicz Hagai

Meray Bassan

Teige Wickenberg Anna Kristina Sveinsdotter

Eli Eyal

Original Assignee

Teva Pharmaceuticals Int Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-21

Filing date

2014-06-19

Publication date

2016-05-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-19 Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh

2016-05-14 Publication of PE20160195A1 publication Critical patent/PE20160195A1/es

Links

YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 4
229950003764 pridopidine Drugs 0.000 title abstract 4
208000023105 Huntington disease Diseases 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 abstract 2
YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 abstract 1
230000000737 periodic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PE2015002618A 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington PE20160195A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361837928P	2013-06-21	2013-06-21
US201361877832P	2013-09-13	2013-09-13

Publications (1)

Publication Number	Publication Date
PE20160195A1 true PE20160195A1 (es)	2016-05-14

Family

ID=52105289

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PE2015002618A PE20160195A1 (es)	2013-06-21	2014-06-19	Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE2016002253A PE20170302A1 (es)	2013-06-21	2014-06-19	Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PE2016002253A PE20170302A1 (es)	2013-06-21	2014-06-19	Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Country Status (24)

Country	Link
US (1)	US10322119B2 (2)
EP (1)	EP3010506B1 (2)
JP (1)	JP2016523862A (2)
KR (1)	KR102316933B1 (2)
CN (1)	CN105592848A (2)
AU (1)	AU2014281414A1 (2)
BR (1)	BR112015029918A2 (2)
CA (1)	CA2913781C (2)
CL (1)	CL2015003690A1 (2)
DK (1)	DK3010506T3 (2)
EA (1)	EA201690069A1 (2)
ES (1)	ES2879631T3 (2)
HK (1)	HK1221646A1 (2)
HU (1)	HUE054783T2 (2)
IL (1)	IL242804B (2)
MX (1)	MX384234B (2)
PE (2)	PE20160195A1 (2)
PH (1)	PH12015502691A1 (2)
PL (1)	PL3010506T3 (2)
SG (1)	SG11201509729YA (2)
TW (1)	TW201529069A (2)
UA (1)	UA122999C2 (2)
UY (1)	UY35624A (2)
WO (1)	WO2014205229A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
JP2013536825A (ja)	2010-09-03	2013-09-26	イバックス・インターナショナル・ゲーエムベーハー	ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
TWI579272B (zh)	2011-12-08	2017-04-21	梯瓦製藥國際有限責任公司	普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
US11090297B2 (en)	2013-06-21	2021-08-17	Prilenia Neurotherapeutics Ltd.	Pridopidine for treating huntington's disease
MX377576B (es) *	2014-01-22	2025-03-04	Prilenia Neurotherapeutics Ltd	Formulaciones de pridopidina de liberación modificada.
TW201613859A (en)	2014-06-30	2016-04-16	Teva Pharma	Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es)	2014-12-22	2018-03-06	Teva Pharmaceuticals Int Gmbh	Sal de l-tartrato de pridopidina.
US11471449B2 (en)	2015-02-25	2022-10-18	Prilenia Neurotherapeutics Ltd.	Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja)	2015-02-25	2021-06-16	プリレニアニューロセラピューティクスリミテッド	認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es)	2015-07-22	2017-10-04	Teva Pharmaceuticals Int Gmbh	Proceso para preparar pridopidina
EP3324967A4 (en) *	2015-07-22	2019-03-20	Prilenia Therapeutics Development Ltd.	PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
JP7034488B2 (ja)	2016-02-24	2022-03-14	プリレニア・ニューロセラピューティクス・エルティーディー	プリドピジンを使用する神経変性眼疾患の治療
EP4516356A3 (en) *	2016-08-24	2025-05-14	Prilenia Neurotherapeutics Ltd.	Use of pridopidine for treating functional decline
CA3035099C (en)	2016-08-24	2023-01-17	Prilenia Therapeutics Development Ltd.	Use of pridopidine for treating dystonias
CN109952100A (zh)	2016-09-15	2019-06-28	普瑞尼亚医疗发展有限公司	普利多匹定用于治疗焦虑和抑郁的用途
HUE058314T2 (hu)	2016-09-16	2022-07-28	Prilenia Neurotherapeutics Ltd	Pridopidin alkalmazása Rett-szindróma kezelésére
US12102627B2 (en)	2016-09-16	2024-10-01	Prilenia Neurotherapeutics Ltd.	Use of pridopidine for treating rett syndrome
CA3050700C (en)	2017-01-20	2023-10-03	Prilenia Neurotherapeutics Ltd.	Use of pridopidine for the treatment of fragile x syndrome
SI4154882T1 (sl) *	2017-08-14	2026-01-30	Prilenia Neurotherapeutics Ltd.	Zdravljenje amiotrofične lateralne skleroze s pridopidinom
CA3073568A1 (en) *	2017-08-30	2019-03-07	Prilenia Neurotherapeutics Ltd.	High concentration dosage forms of pridopidine
US12036213B2 (en)	2017-09-08	2024-07-16	Prilenia Neurotherapeutics Ltd.	Pridopidine for treating drug induced dyskinesias
JP2020533296A (ja)	2017-09-08	2020-11-19	プリレニアニューロセラピューティクスリミテッド	薬物誘発性ジスキネジアを治療するためのプリドピジン
WO2020157083A1 (en) *	2019-01-31	2020-08-06	F. Hoffmann-La Roche Ag	Assessing progression of huntington's disease
CN113395964A (zh)	2019-02-04	2021-09-14	普瑞尼亚神经治疗有限公司	用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
CN121243170A (zh) *	2019-06-12	2026-01-02	普瑞尼亚神经治疗有限公司	用于治疗亨廷顿病及其症状的包含普利多匹定及其类似物的组合物
EP4030993B1 (en) *	2019-09-17	2026-04-15	F. Hoffmann-La Roche AG	Improvements in personalized healthcare for patients with movement disorders
WO2022094565A1 (en) *	2020-10-28	2022-05-05	Buck Institute For Research On Aging	N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders
WO2025181805A1 (en) *	2024-02-27	2025-09-04	Prilenia Neurotherapeutics Ltd.	Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904724D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
EP1713486A4 (en)	2003-12-02	2009-04-29	Sheldon Leslie James	COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
CA2584831C (en)	2004-10-13	2013-09-17	Neurosearch Sweden Ab	Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP1815857A1 (en)	2006-02-02	2007-08-08	LEK Pharmaceuticals D.D.	A pharmaceutical composition comprising perindopril
CN101711236B (zh)	2007-04-12	2012-10-31	Nsab神经研究瑞典公司分公司	表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
US8669048B2 (en)	2008-06-24	2014-03-11	Parkinson's Institute	Pluripotent cell lines and methods of use thereof
US8384755B2 (en)	2009-08-26	2013-02-26	Intouch Technologies, Inc.	Portable remote presence robot
US20110206782A1 (en)	2010-02-24	2011-08-25	Auspex Pharmaceuticals, Inc.	Piperidine modulators of dopamine receptor
WO2011107583A1 (en) *	2010-03-04	2011-09-09	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013536825A (ja)	2010-09-03	2013-09-26	イバックス・インターナショナル・ゲーエムベーハー	ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt)	2011-09-07	2018-04-03	Ivax Int Gmbh	Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) *	2011-12-08	2017-04-21	梯瓦製藥國際有限責任公司	普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
US9744155B2 (en)	2012-03-28	2017-08-29	Ixcela, Inc.	IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
AU2013243461A1 (en)	2012-04-04	2014-11-06	Teva Pharmaceuticals International Gmbh	Pharmaceutical compositions for combination therapy
US20150216850A1 (en)	2012-09-27	2015-08-06	Michael Hayden	Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003608A (es)	2012-09-27	2015-06-05	Teva Pharma	Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
MX377576B (es)	2014-01-22	2025-03-04	Prilenia Neurotherapeutics Ltd	Formulaciones de pridopidina de liberación modificada.
TW201613859A (en)	2014-06-30	2016-04-16	Teva Pharma	Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es)	2014-12-22	2018-03-06	Teva Pharmaceuticals Int Gmbh	Sal de l-tartrato de pridopidina.
WO2016138135A1 (en)	2015-02-25	2016-09-01	Teva Pharmaceuticals International Gmbh	Sigma-1 receptor modulators for treating huntington's disease
JP6887952B2 (ja)	2015-02-25	2021-06-16	プリレニアニューロセラピューティクスリミテッド	認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es)	2015-07-22	2017-10-04	Teva Pharmaceuticals Int Gmbh	Proceso para preparar pridopidina
EP3324967A4 (en)	2015-07-22	2019-03-20	Prilenia Therapeutics Development Ltd.	PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
WO2017048457A1 (en)	2015-09-18	2017-03-23	Teva Pharmaceuticals Industries Ltd.	Combination of laquinimod and pridopidine to treat multiple sclerosis
CA3035099C (en)	2016-08-24	2023-01-17	Prilenia Therapeutics Development Ltd.	Use of pridopidine for treating dystonias
EP4516356A3 (en)	2016-08-24	2025-05-14	Prilenia Neurotherapeutics Ltd.	Use of pridopidine for treating functional decline
CN109952100A (zh)	2016-09-15	2019-06-28	普瑞尼亚医疗发展有限公司	普利多匹定用于治疗焦虑和抑郁的用途
HUE058314T2 (hu)	2016-09-16	2022-07-28	Prilenia Neurotherapeutics Ltd	Pridopidin alkalmazása Rett-szindróma kezelésére
WO2018053275A1 (en)	2016-09-16	2018-03-22	Teva Pharmaceuticals International Gmbh	Use of pridopidine for the treatment of familial dysautonomia

2014
- 2014-06-19 HK HK16109788.9A patent/HK1221646A1/zh unknown
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 MX MX2015017307A patent/MX384234B/es unknown
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en not_active Ceased
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active Active
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown

Also Published As

Publication number	Publication date
EA201690069A1 (ru)	2016-06-30
MX2015017307A (es)	2016-08-03
US10322119B2 (en)	2019-06-18
TW201529069A (zh)	2015-08-01
PE20170302A1 (es)	2017-03-31
KR20160055122A (ko)	2016-05-17
AU2014281414A1 (en)	2016-01-21
DK3010506T3 (da)	2021-07-12
HUE054783T2 (hu)	2021-09-28
SG11201509729YA (en)	2015-12-30
WO2014205229A8 (en)	2015-04-09
EP3010506A4 (en)	2017-02-08
UY35624A (es)	2015-01-30
CA2913781A1 (en)	2014-12-24
KR102316933B1 (ko)	2021-10-26
CL2015003690A1 (es)	2016-10-28
MX384234B (es)	2025-03-14
PH12015502691A1 (en)	2016-03-14
JP2016523862A (ja)	2016-08-12
WO2014205229A1 (en)	2014-12-24
PL3010506T3 (pl)	2021-11-02
IL242804B (en)	2022-02-01
EP3010506A1 (en)	2016-04-27
CA2913781C (en)	2022-05-10
BR112015029918A2 (pt)	2017-07-25
ES2879631T3 (es)	2021-11-22
EP3010506B1 (en)	2021-05-12
HK1221646A1 (zh)	2017-06-09
UA122999C2 (uk)	2021-02-03
CN105592848A (zh)	2016-05-18
US20140378508A1 (en)	2014-12-25

Legal Events

Date	Code	Title	Description
2016-11-16	FA	Abandonment or withdrawal

Publication	Publication Date	Title
PE20160195A1 (es)	2016-05-14	Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
CL2019003924A1 (es)	2020-05-29	Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
NI201100147A (es)	2011-11-09	Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
BR112015029512A2 (pt)	2017-07-25	derivados de pirazolopirrolidina e seu uso no tratamento de doenças
PE20150161A1 (es)	2015-02-22	Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
EA201370230A1 (ru)	2014-02-28	Новые ингибиторы rock
BR112015009504A2 (pt)	2017-07-04	inibidores de rock
BR112015029401A8 (pt)	2020-03-17	derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MX2021015543A (es)	2022-04-25	Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
CL2021003312A1 (es)	2022-08-26	Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
MX2022015629A (es)	2023-01-11	Uso de vibegron para tratar vejiga sobreactiva.
PE20181332A1 (es)	2018-08-20	Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
EP4700016A3 (en)	2026-03-25	Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
AR073265A1 (es)	2010-10-28	Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
AR080096A1 (es)	2012-03-14	Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
UY35890A (es)	2015-07-31	Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR074246A1 (es)	2011-01-05	Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
MX2019003720A (es)	2019-09-19	Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2021007324A (es)	2021-08-16	Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202090416A1 (ru)	2020-05-25	Способы лечения симптомов гастропареза с использованием велусетрага
EA202190247A1 (ru)	2021-06-10	ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
AR059219A1 (es)	2008-03-19	Uso de la suramina para la preparacion de un medicamento para inhibir la neovascularizacion retinal y corneal
EA201992690A1 (ru)	2020-05-14	Применение вибегрона для лечения гиперактивного мочевого пузыря
AR061355A1 (es)	2008-08-20	Preparaciones de combinacion que comprenden slv308 y l-dopa
EA201990553A1 (ru)	2019-08-30	Применение придопидина для лечения ухудшения функциональной способности